MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

MCK · NYSE

McKesson Corporation

Health Care · Other Pharmaceuticals

Reference price$874.72As of Jul 30, 2026
Market capitalization$105B
52-week range$637.00–$999.00
S&P 500 portfolio weight0.17%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$812.00-7.2% vs. reference
Average$936.08+7.0% vs. reference
High$1,050.00+20.0% vs. reference
11 Buy2 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 5, 2026Jun 2026
Consensus EPS$9.445 estimates
Expected range$9.25–$9.65Low to high EPS
Mar 2027$44.28Street EPS consensus
Mar 2028$49.96Street EPS consensus
Mar 2029$56.69Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Mar 31, 2026.

MetricCurrentPrior
Revenue+12.4% YoY$403B$359B
Operating income$6.21B$4.42B
Net income$4.76B$3.3B
Operating cash flow$6.16B$6.09B
Capital expenditures($0.44B)($0.54B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

GEHC Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market

BNK Invest

Notable ETF Inflow Detected - PVAL, ALL, LUV, MCK

Zacks

Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.